0 9 - 6
U.S. Patent

9-24-03 PTO/SB/21 (08-03) Approved for use through 08/30/2003, OMB 0651-0031

Linder the Panerwork Reduction Ac	et of 1995, no persor	U.S. Patens are required to respond to a collect	ent and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it displays a valid OMB control number.				
S)	CO TOO TO DO TO	Application Number	10/643,824				
TRANSMITTA	۱L	Filing Date					
FORM (to be used for all correspondence after initial filing)		First Named Inventor	Nelson, Ernest Peter				
		Art Unit					
		Examiner Name					
Total Number of Pages in This Submi	ission 43	Attorney Docket Number					
ENCLOSURES (Check all that apply)							
Fee Transmittal Form		Drawing(s)	After Allowance communication to Technology Center (TC)				
Fee Attached		Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply		Petition .	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)				
After Final		Petition to Convert to a Provisional Application	Proprietary Information				
Affidavits/declaration	n(s)	Power of Attorney, Revocation Change of Correspondence Add	dress Status Letter				
			Other Enclosure(s) (please Identify below):				
Extension of Time Request		Terminal Disclaimer Request for Refund	identity below).				
Express Abandonment Requ		·					
Information Disclosure State	ement L Rema	CD, Number of CD(s)					
Certified Copy of Priority Document(s)	110						
Response to Missing Parts/	,						
Incomplete Application							
Response to Missing							
under 37 CFR 1.52	or 1.53						
	CIONATURE	OF ADDITIONAL ATTOR	NEV OR ACENT				
		OF APPLICANT, ATTOR	NET, OR AGENT				
or Keeling Hudson,							
Signature	Alle	. 0 -					
Date							
	CERTIE	ICATE OF TRANSMISSIO	DN/MAILING				
I haraby cartify that this correspond			or deposited with the United States Postal Service with				
sufficient postage as first class mail	l in an envelope a	ddressed to: Commissioner for F	Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on				
Typed or printed name	A. Keeling						
Signature	4		Date 9-23-03				
	_ , , , , ,		1 10000				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ernest Peter Nelson

Serial No.: 10/643,824 Group No.:

Filed: Examiner:

For: LEG USCER, LYMPHOEDEMA AND DVT VIBRATORY TREATMENT DEVICE

Commissioner for Patents Washington DC 20231

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

- 1. Preliminary Statements
- 2. Forms PTO 1449 (now PTO/SB/08A and 08B)
- 3. Copies of Listed Information Items Accompanying This Statement
- 4. Concise Explanation of English Language Listed Information Items
- 5. Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary Statements

Applicant(s) submits herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR 1.97(g)), an admission that the information

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as attached thereto are being deposited with the United States Postal Service on the date listed below, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number <u>ER 216 164 121 US</u>, addressed to the: Commissioner for Patents, Washington, DC 20231.

9-23-03

Date

Kenneth A. Keeling Registration No. 31,842 cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. PTO 1449 (Now Forms PTO/SB/08A and 08B)

PTO Form 1449 is attached hereto.

Section 3. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Form PTO-1449 accompany this information statement.

Section 4. Concise Explanation of English Language Listed Information Items

- 1. "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and on Wound Healing," presented at the VII International Congress of Lymphology, Firenze, Italy on October 28 to November 2, 1979 by Lievens, Leduc and Dewald Suggests that some aspects of wound healing in test mice were improved by a regime of cycloidal vibrations.
- 2. "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain," presented to the Section of Dermatology of the Royal Society of Medicine in 1978 by Pickup, Alexander, and Gosling Discloses that while vibration was recognized to dramatically reduce pain from leg ulcers, only a slight improvement in healing was noticed.
- 3. "The Effects of Vibration Upon Blood-Viscosity and Red-Cell Mobility: A Study In Vivo and In-Vitro," by Ramcharan, Shoja, Piggott and Taylor, published in Biorheology Vol. 19, pages 341 to 352 in 1982

Presents studies of three dimensional, or "cycloid" vibration showing that vibration of either human or rabbit blood in vitro has no effect on blood-viscosity at any sheer rate, on red cell mobility, on zeta-potential or on yield stress. Whole-body vibration produced no significant effect on rheology at rates of shear above 2 s-l, but low-shear viscosity (<1 s-l Shear rate) became more Newtonian after vibration, with a significant reduction in yield stress from 5.71 +/-0.14 mNm-2 to 3.54 +/- 0.32 mNm-2.

4. "The Effects of Vibration on Skin Blood Flow," by Ryan and Salter, published in Biblotheca Anatomica, No. 16, pages 180 – 184 in 1977 and presented at the 9th European Conference of Microcirculation in Antwerp, Belgium in 1976

Presents interpretation on effect of vibration. Concludes that the effect of vibration is primarily to disperse tissue fluid, which is therapeutically useful for conditions where stiffness, pain or swelling are directly related to an excess of fluid in the tissues.

5. "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Vibration Therapy by Askari and Rozov (No publication date is available)

Presents a trial study of applying cycloid vibration to patients with cases of severe occlusive peripheral vascular disease.

Section 5. Identification of Person(s) Making This Information Disclosure Statement

The pe	erson making th	nis statement is:			
(a)	☐ the invent	tor(s) who signs below.			
(b)	an individual associated with the filing and prosecution of this application.				
(c)	■ the practitioner who signs below on the basis of the information:				
		supplied by the inventor(s). supplied by an individual associated with the filing and prosecution of this application (37 CFR 1.56(c))			
		in the practitioner's file.			

Respectfully submitted,

Kenneth A. Keeling Registration No. 31,842 James E. Hudson III Registration No. 41,081

September 2**3**, 2003 Keeling Hudson L.L.C. 901 North Post Oak Road Houston, Texas 77024 713-680-1447 713-680-8567 (Fax) Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent

Sheet

Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	/	LIEVENS, LEDUC, DEWALD, "The Use of Cycloidal Vibrations Therapy on Blood and Lymph Circulation and		
		on Wound Healing," VII International Congress of Lymphology, 10/28/1979 to 11/2/1979, Firenze, Italy		
		PICKUP, ALEXANDER, GOSLING, "The Effect of cycloid Vibration on Leg Blood Flow and Ulcer Pain,"		
		Section of Dermatology of the Royal Society of Medicine, 1978.		
		RAMCHARAN, SHOJA, PIGGOTT, TAYLOR, "The Effects of Vibration Upon Blood-Viscosity and Red-Cell		
		Mobility: A Study In Vivo and In-Vitro," Biorheology, 1982, Vol 19, Pergamon Press Ltd., USA.		
	/	RYAN, SALTER, "The Effects of Vibration on Skin and Blood Flow," Biblotheca Anatomica, 1977, Vol. 16		
		S. Karger, Basel, Switzerland		
		ASKARI, ROZOV, "Improvement of Blood Flow in Ischaemic Limbs by the Use of Cycloid Therapy," Israel,		
		Other publication information not available.		

Examiner	1	Date	002-02
Signature		Considered	905-05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.